[go: up one dir, main page]

DK1750668T3 - Liquids containing suspended glass particles - Google Patents

Liquids containing suspended glass particles

Info

Publication number
DK1750668T3
DK1750668T3 DK05731023.7T DK05731023T DK1750668T3 DK 1750668 T3 DK1750668 T3 DK 1750668T3 DK 05731023 T DK05731023 T DK 05731023T DK 1750668 T3 DK1750668 T3 DK 1750668T3
Authority
DK
Denmark
Prior art keywords
glass particles
liquids containing
particles
containing suspended
suspended glass
Prior art date
Application number
DK05731023.7T
Other languages
Danish (da)
Inventor
Bruce Joseph Roser
Original Assignee
Nova Bio Pharma Technologies L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Bio Pharma Technologies L filed Critical Nova Bio Pharma Technologies L
Priority claimed from PCT/GB2005/050050 external-priority patent/WO2005099669A1/en
Application granted granted Critical
Publication of DK1750668T3 publication Critical patent/DK1750668T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

A pharmaceutical composition comprising a biologically active agent preserved in particulate form, in particular a glass or amorphous particle, such as a sugar, a metal carboxylate, an amino acid or calcium phosphate, wherein said particles are suspended in at least one of a hydrofluoroether, a perfluoroether, a hydrofluoroamine, a perfluoroamine, a hydrofluorothioether, a perfluorothioether, a hydrofluoropolyether or a perfluoropolyether. The use of such fluorinated liquid media overcomes the problem of aggregation of particles and also is environmentally friendly.
DK05731023.7T 2004-04-13 2005-04-13 Liquids containing suspended glass particles DK1750668T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0408199.8A GB0408199D0 (en) 2004-04-13 2004-04-13 Liquids containing suspended sugar glass particles
GB0504501A GB2413075B (en) 2004-04-13 2005-03-07 Liquids containing suspended glass particles
PCT/GB2005/050050 WO2005099669A1 (en) 2004-04-13 2005-04-13 Liquids containing suspended glass particles

Publications (1)

Publication Number Publication Date
DK1750668T3 true DK1750668T3 (en) 2010-05-10

Family

ID=32320732

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05731023.7T DK1750668T3 (en) 2004-04-13 2005-04-13 Liquids containing suspended glass particles

Country Status (10)

Country Link
CN (1) CN1942171B (en)
AT (1) ATE457717T1 (en)
DE (1) DE602005019398D1 (en)
DK (1) DK1750668T3 (en)
ES (1) ES2339783T3 (en)
GB (2) GB0408199D0 (en)
MX (1) MXPA06011895A (en)
PT (1) PT1750668E (en)
RU (1) RU2363447C2 (en)
ZA (1) ZA200609158B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
GB0523638D0 (en) 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
US9243626B2 (en) 2012-11-19 2016-01-26 Nordson Corporation Adhesive dispensing system and method including a pump with integrated diagnostics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258027A (en) * 1994-03-16 1995-10-09 Shiseido Co Ltd Makeup cosmetic
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6190701B1 (en) * 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
AU2046101A (en) * 1999-11-22 2001-06-04 Universal Preservation Technologies, Inc. Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
US6562872B1 (en) * 2000-07-20 2003-05-13 Otkrytoe Aktsionernoe Obschestvo Naucho-Proizvodstven-Naya Firma “Perftoran” Emulsion of perfluoroorganic compounds for medical purposes, a process for the preparation thereof and methods for treating and preventing diseases with the use thereof
PL360052A1 (en) * 2000-10-13 2004-09-06 Cambridge Biostability Ltd. Composition and method for stable injectable liquids

Also Published As

Publication number Publication date
GB2413075A (en) 2005-10-19
GB0408199D0 (en) 2004-05-19
ES2339783T3 (en) 2010-05-25
ZA200609158B (en) 2008-06-25
MXPA06011895A (en) 2007-11-20
RU2006137275A (en) 2008-05-20
DE602005019398D1 (en) 2010-04-01
ATE457717T1 (en) 2010-03-15
CN1942171B (en) 2011-04-06
PT1750668E (en) 2010-04-07
GB0504501D0 (en) 2005-04-13
GB2413075B (en) 2009-01-21
CN1942171A (en) 2007-04-04
RU2363447C2 (en) 2009-08-10

Similar Documents

Publication Publication Date Title
ATE529499T1 (en) GRANULES OF A SENSITIVE DETERGENT OR CLEANING INGREDIENT
GB2464038A (en) System, method, and apparatus for combined fracturing treatment and scale inhibition
EP2293808A4 (en) SYNTHETIC PEPTIDE CONTAINING OSTEOGENIC PEPTIDE 1 (BFP 1) FOR THE STIMULATION OF OSTEOBLASTIC DIFFERENTIATION, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SYNTHETIC PEPTIDE
EA200802140A1 (en) LIQUID COMPOSITION CONTAINING THE ASPARAGIN PROTEAS
UA96473C2 (en) Liquid stable formulation comprising imc-a12 antibody
EP2335575A3 (en) Magnetic gas bubble composition and magnetic gas bubble precursor for its manufacture
ATE541928T1 (en) RIBONUCLEOTIDE REDUCTASE SUBUNITY 2 INHIBITORS AND USES THEREOF
BR0214279A (en) Pharmaceutical compositions in particulate form
NZ629261A (en) Pharmaceutical formulations of tnf-alpha antibodies
EP1988159A4 (en) CULTURE MEDIUM ADDITIVE FOR ANIMAL CELL FREE SERUM, KIT AND USE OF THE ADDITIVE OR KIT
Moelants et al. Citrullination and proteolytic processing of chemokines by Porphyromonas gingivalis
SE0100823D0 (en) Method I to obtain microparticles
ATE442869T1 (en) SUSPENSION TO REDUCE ODOR
ATE458256T1 (en) HIGH SWITCHING FACTOR MAGNETORHEOLOGICAL MATERIALS AND THEIR USE
DK1750668T3 (en) Liquids containing suspended glass particles
FR2881648B1 (en) COSMETIC COMPOSITION COMPRISING A POLYMER PARTICLE DISPERSION, POLYMER PARTICLE DISPERSION AND COSMETIC PROCESS USING THE SAME
TR200102988T2 (en) Absorbents for use in handling complex liquids.
WO2007111681A3 (en) Device and methods for liquid crystal-based bioagent detection
DE502005005891D1 (en) NEW HYDROGELS BASED ON POLYVINYL ALCOHOLS AND POLYVINYL ALCOHOL COPOLYMERS
DE602007005146D1 (en) AMMENSETZUNG
FR2869510A1 (en) CONDITIONING AND APPLICATION DEVICE COMPRISING A MAGNETIC MEDIUM AND AN APPLICATION BODY
EP2011494A4 (en) DYSPHAGIA MITIGATION AGENT AND PHARMACEUTICAL OR FOOD COMPOSITION CONTAINING THE SAME
DE602004009731D1 (en) Solid dosage form containing caffeine
RU2009101093A (en) METHOD FOR INTRODUCING PROTECTIVE ENVIRONMENT IN BIOLOGICALLY ACTIVE MATERIAL
FI20040813L (en) Proteins that stabilize hydrophobic molecules